Therapeutic Asset Ratings

allogeneic natural killer (NK) cells isolated from peripheral blood leukapheresis of individual donors. The cells are co-cultured in media containing interleukin 15 (IL-15) and nicotinamide (NAM, niacinamide) with expansion enhanced by the presence of feeder cells. The final cell population consists of 97-99% CD3-CD56+ NK cells, with >10% expressing CD16 (also known as Fc?RIII) and CD62L (also known as L-selectin) and with capacity to degranulate (surface expression of CD107? [Lysosome-associated membrane glycoprotein 1]; >10%), and to kill target cells (>10%) in co-culture assays against human cancer cell lines.

cd19-ucart

Ngfr-Transduced Autologous T Lymphocytes

TIL

Tisagenlecleucel

Tumor Antigen Loaded Autologous Dendritic Cells

Equecabtagene Autoleucel

Idecabtagene Vicleucel

Autologous Cd1C+ /Cd141+ Mydc

autologous CD3+ enriched T lymphocytes obtained from peripheral blood mononuclear cells (PBMCs) by apheresis. The cells are transduced with a self-inactivating, non-replicating lentiviral vector encoding an enhanced-affinity T cell receptor (TCR) targeting the HLA-A*02:01-restricted MAGE-A4 peptide (GVYDGREHTV) alongside the CD8 alpha (CD8?) co-receptor. The expressed transgene comprises the coding sequence for the CD8? co-receptor, separated by a foot-and-mouth disease virus 2A self-cleaving peptide sequence from the coding sequence of the MAGE-A4 T-cell receptor alpha and beta chains that are separated from each other by a porcine teschovirus-1 2A self-cleaving peptide sequence, under control of the human elongation factor 1 alpha (EF-1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a tRNA primer binding site, a ? packaging signal, a truncated gag, a Rev response element (RRE) and a central polypurine tract (cPPT) sequence 5' to the transgene, and a polypurine tract (PPT) 3' to the transgene. The vector is pseudotyped with the vesicular stomatitis virus (VSV) G envelope glycoprotein. The CD3+ T lymphocytes are purified and activated using anti-CD3/anti-CD28 monoclonal antibody coated magnetic beads. The cells are then cultured in media containing interleukin 2 (IL-2), human AB serum and a protein kinase B (AKT inhibitor). The cells are CD3+ (> 80%), express the high affinity MAGE-A4 specific TCR and CD8? co-receptor (CD8? +TCR+; >16%) and are cytotoxic to MAGE-A4 expressing tumor cells

Ciltacabtagene Autoleucel

Dilanubicel

Dilanubicel

Dilanubicel

GEMOGENOVATUCEL-T

Human Bcma Targeted T Cells

Kras Tcr-Transduced Pbl

cd22 car-t

cd22 car-t

cd5-targeted car-t cells

Haescs

im96 car-t cells

NKG2D CAR-NK

TIL

TIL